Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Number of Participants With Abnormalities in Laboratory Test (Without Regard to Baseline Abnormality)

Laboratory tests included hematology(hemoglobin,hematocrit,red and white blood cell count,mean corpuscular volume,mean corpuscular hemoglobin,mean corpuscular hemoglobin concentration,platelet count,neutrophils,eosinophils,monocytes, basophils,lymphocytes), chemistry(blood urea nitrogen/urea and creatinine,fasting glucose, calcium,sodium,potassium, chloride,total carbon dioxide,aspartate and alanine aminotransferase,total bilirubin,alkaline phosphatase,uric acid,albumin,total protein),urinalysis(pH,qualitative glucose protein,blood,ketones,nitrites,leukocyte esterase,urobilinogen,urine bilirubin,microscopy,specific gravity,urine creatinine),other tests(urine drug screen,follicle stimulating hormone,anti neutrophil cytoplasmic antibody panel,qualitative antinuclear antibody,fibrinogen,C reactive protein,erythrocyte sedimentation rate,C3, C4, CH50/CH100,rheumatoid factor,immunoglobulin panel,if anti- neutrophil cytoplasmic antibody positive:proteinase 3 Ab,myeloperoxidase Ab tests).

Time frame: Baseline to last visit after termination(up to approximately 3 months)

Number of Participants With Vital Signs Data Meeting Pre-defined Criteria

Number of participants with vital signs findings meeting the following criteria is presented:(1) standing DBP increase from baseline\>= 20 mm Hg; (2) standing SBP increase from baseline\>= 30 mm Hg; (3) supine DBP increase from baseline \>=20 mm Hg; (4) supine SBP increase from baseline \>=30 mm Hg; (5)standing DBP decrease from baseline\>= 20 mm Hg; (6) standing SBP decrease from baseline\>= 30 mm Hg; (7) supine DBP decrease from baseline \>=20 mm Hg; (8) supine SBP decrease from baseline \>=30 mm Hg.

Time frame: Baseline to last visit after termination (up to approximately 3 months)

Number of Participants With Vital Signs Data of Orthostatic Hypotension Meeting Pre-defined Criteria

Orthostatic hypotension was defined as a decrease of \>=20 mmHg for systolic blood pressure (SBP) or \>=10 mmHg for diastolic blood pressure (DBP) 2 minutes after standing from a supine position.

Time frame: Baseline to last visit after termination (up to approximately 3 months)

Number of Participants With Electrocardiogram Data Meeting Pre-defined Criteria

PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization), QRS duration (time from Q wave to the end of S wave, corresponding to ventricle depolarization), QT interval (time from the beginning of Q wave to the end of T wave) and QTcF interval ( QT interval corresponding to electrical systole corrected for heart rate using Fridericia's formula) are summarized. Number of participants with ECG findings meeting the following criteria is presented: (1) PR interval \>=300 msec; (2) QRS duration \>=140 msec; (3) QT interval \>= 500; (4) QTcF interval: 450 to \<480 msec; (5) QTcF interval: 480 to \<500 msec; (6) QTcF interval \>=500 msec.

Time frame: Baseline to last visit after termination (up to approximately 3 months)

Number of Participants With Worsening Suicidality and New Onset Suicidality

The Columbia Suicide Severity Rating Scale (C-SSRS) is an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. At each suicidality assessment, participants felt to have significant suicidal ideation with actual plan and intent or suicidal behavior, must be evaluated by a clinician/mental health professional (MHP) skilled in the evaluation of suicidality in the participants by virtue of training or experience who determined if it is safe for the participants to participate/continue in the trial. The denominator used in the percentages was the number of participants assessed for suicidality or worsening, the denominator included the subset of participants who had any level of suicidality reported at baseline. For new onset, the denominator included the subset of participants with no suicidality reported at baseline.

Time frame: Baseline to last visit after termination (up to approximately 3 months)

Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20)

The PWC-20 is a physician-completed, 20-item reliable and sensitive instrument for the assessment of benzodiazepine discontinuation symptoms, including anxiety and nervous, depersonalization and derealization, diarrhea, diaphoresis, difficulty concentrating and remembering, dizziness-lightheadedness, depression, fatigue, lethargy and lack of energy, headaches, increased acuity for sound, smell, touch, or pain, insomnia, irritability, loss of appetite, muscle aches or stiffness, nausea-vomiting paresthesias, poor coordination, restlessness and agitation, tremor-tremulousness, and weakness. Summaries of the count of participants experiencing symptoms and severity listed in the PWC-20 were provided.

Time frame: At last visit